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Abstract
Background and Aims: to review the regenerative technologies used in bone 
regeneration: bone grafts, barrier membranes, bioactive factors and cell therapies 
Material and Methods: four background review publications served to elaborate this 
consensus report 
Results and Conclusions: Biomaterials used as bone grafts must meet specific 
requirements: biocompatibility, porosity, osteoconductivity, osteoinductivity, surface 
properties, biodegradability, mechanical properties, angiogenicity, handling and 
manufacturing processes. Currently used biomaterials have demonstrated 
advantages and limitations based on the fulfillment of these requirements. Similarly, 
membranes for guided bone regeneration (GBR) must fulfill specific properties and 
potential biological mechanisms to improve their clinical applicability. Pre-clinical and 
clinical studies have evaluated the added effect of Bone Morphogenetic Proteins 
(mainly BMP-2) and Autologous Platelet Concentrates (APCs) when used as 
Page 2 of 25
Journal of Clinical Periodontology - PROOF
Journal of Clinical Periodontology - PROOF
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3
bioactive agents to enhance bone regeneration. Three main approaches using cell 
therapies to enhance bone regeneration have been evaluated: a) “minimally 
manipulated” whole tissue fractions; b) ex-vivo expanded “uncommitted” 
stem/progenitor cells, and c) ex-vivo expanded “committed” bone-/periosteum-
derived cells. Based on the evidence from clinical trials, transplantation of cells, most 
commonly whole BMA or BMAC, in combination with biomaterial scaffolds has 
demonstrated an additional effect in sinus augmentation and horizontal ridge 
augmentation, and comparable bone regeneration to autogenous bone in alveolar 
cleft repair. 
Page 3 of 25
Journal of Clinical Periodontology - PROOF
Journal of Clinical Periodontology - PROOF
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4
Introduction
This consensus report aims to describe the regenerative technologies currently used 
in bone regenerative interventions in the craniomaxillofacial region. The relevant 
scientific evidence that served to elaborate this report came from four background 
publications, being three narrative reviews using a systematic search approach and 
one systematic review, respectively:  
1. Bone grafts: which is the ideal biomaterial? Haugen HJ, Lyngstadaas SP, 
Rossi, F and Perale G
2. Barrier membranes: more than the barrier effect? Omar O, Elgali I, Dahlin C 
and Thomsen P
3. The use of bioactive factors to enhance bone regeneration. A narrative review 
Donos N, Dereka X and Calciolari E
4. Cell therapy for orofacial bone regeneration: a systematic review and meta-
analysis Shanbhag S, Suliman S, Pandis N, Stavropoulos A,  Sanz M and 
Mustafa K
Biomaterials used as bone replacement grafts in regenerative 
interventions in the cariomaxillo-facial region 
Biomaterials used as bone replacement grafts must meet specific requirements to 
achieve the goal of developing a new and healthy bone tissue formation:  
-  Biocompatibility. The interaction between the material and the tissues should not 
adversely affect the surrounding tissues, the intended healing result or the safety 
of the patient. (Williams, 2017). Ideally, biomaterials should be inherently bioactive 
in promoting the bone regeneration process (e.g. ion release, surface 
characteristics, etc.).
- Porosity. An adequate pore size, morphology and inter-connectivity is needed to 
allow for diffusion throughout the whole scaffold of bone cells, nutrients and 
exchange of waste products. It is important to distinguish between micro-porosity 
and macro-porosity (Hutmacher, 2000). Micro-porosity is defined as pores ≤ 10 µm 
o improve cell adhesion, to allow fluids and nutrients flow (permeability) and thus 
to enhance the bioactivity. Macro-porosity is defined as pores ≥ 100 µm to allow 
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for angiogenesis and to bone cell ingrowth, thus mimicking the porosity of 
trabecular bone, which has a mean value 250 µm, although it is highly variable. 
Inter-connectivity (the connection between pores) is also an important property to 
allow for permeability, vascularization and bone ingrowth.
- Osteoconductivity/ Osteoinductivity. All biomaterials used for bone regeneration 
should allow for bone growth directly in contact with the biomaterial surface from 
the surrounding bone (osteoconduction), but ideally it should also be able to 
promote osteoinduction (Albrektsson, 2001). An osteoinductive biomaterial should 
first be capable of recruiting mesenchymal-type osteoprogenitor cells. Secondly, it 
should be capable of transforming an undifferentiated mesenchymal cell into a 
mature, bone-forming osteoblast. Lastly, it should be capable of inducing in-growth 
of ectopic bone formation when implanted into extra-skeletal locations. This 
capacity may be related to its micro-porosity and surface properties.
- Surface properties. Surface topography at the nano and micro level as well as 
surface physico-chemistry are important characteristics for protein adsorption, 
extracellular matrix deposition, cell adhesion, differentiation, migration and finally 
bone formation. 
- Biodegradability. The capacity of the biomaterial to bio-absorb during the tissue 
healing and remodeling process. The ideal bone graft substitute is expected to be 
fully replaced by bone, preferably at a predictable absorption rate, without losing 
tissue volume and without interfering with the healing and regeneration process. In 
case of biomaterials with a slow bio-absorbability rate, these should assure a 
process of new bone formation with sufficient volume in contact with the 
biomaterial.
- Mechanical properties. Compressive strength and elasticity should be high enough 
to absorb the load from the surrounding hard and soft tissues in non-contained 
defects. Ideally the compressive strength and elasticity of the biomaterial should 
be at least those of the natural bone at the site of regeneration. These mechanical 
properties are also influenced by pore morphology and size. 
- Angiogenicity. The inherent biomaterial properties (porosity, surface, etc.) should 
promote angiogenesis and the appropriate vascularization of the graft volume.
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- Handling. The biomaterial should be cohesive and dimensionally stable, easy for 
chairside use to adapt to the defect. When used in non-contained defects, it 
should allow for three-dimensional build up. Biomaterials for craniomaxillo-facial 
bone regeneration are usually available in the form of granules or blocks. 
Depending on the clinical needs, it is desirable to have a wide variability of sizes 
and forms, ranging from 0.1 mm-2.0 mm in the particulate form. For certain 
indications an injectable mode of application would be desired to fill the defect 
volume through its plasticity.
- Manufacturing processes. The biomaterial should be provided with certification or 
documentation of the appropriate manufacturing and sterilization processes and 
assure long shelf time and reduced production costs.
Which are the advantages and limitations of the currently used bone grafts for 
craniomaxillo-facial bone regeneration?
Autologous
Even though autologous bone is not a biomaterial per se, it is considered the gold 
standard graft material for bone regeneration and it has the following advantages: it 
contains the patient’s own cells, growth factors and bio-molecules needed for 
osteogenesis, it has the highest degree of biological safety, biocompatibility, 
matched mechanical properties and scaffolding effect.
In regard to limitations, autologous grafts may need a second surgical site for its 
harvesting, which increases patient’s morbidity, pain or discomfort and other 
complications related to increased surgical time and invasiveness. It has been 
reported that the resorption of these bone replacement grafts is higher, and their rate 
of resorption is not predictable. Depending on the source of the graft (cortical versus 
cancellous bone) the vascularization may be slowed, mainly in highly cortical bone 
grafts. It has also limitations in terms of volume availability, mainly when harvesting 
from intraoral sources and the resulting grafts, mainly in a block form may be difficult 
to adapt to the anatomy of the defect. 
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The application of particulate dentin has been recently suggested as another 
autologous source for minor ridge augmentation or socket site preservation. 
However, there is no clinical documentation to substantiate its clinical use.
Allogenic
There are different ways of processing allogenic bone replacement grafts (freeze 
dried, fresh frozen, etc.), which may change their biological properties. These 
allografts can be produced as particulate or blocks. In principle, the general 
advantage of this biomaterial is that it provides similar mechanical properties as the 
autologous bone and it may contain the collagenous matrix and proteins of natural 
bone, although it lacks viable cells. Similarly, handling properties are comparable to 
autologous bone, although the reduced surgical time needed for their implantation, in 
addition to their increased availability are clear advantages when compared with 
autologous bone.
Its biological safety due to possible disease transmission and potential unwanted 
immune reactions are clear disadvantages. Furthermore. the sources of donor 
material are heterogeneous, what may influence their biological activity and similarly, 
resorption rate are highly variable. Other drawbacks could be possible impairment to 
achieve vascularization of the grafted site. In the future its availability for clinical use 
may be reduced in light of the regulatory changes in Europe.
Xenogeneic
This is the biomaterial with the most documentation in the scientific literature for 
bone grafting in the cranio-maxillo-facial area. Its main advantages are that since it is 
derived from both natural cancellous and cortical bone its architecture and geometric 
structure resemble bone, although highly depending on the tissue source and 
manufacturing process. Its slow bio-absorbability may be a clinical advantage for 
preserving the augmented bone volume. 
In regard to limitations, it lacks biological components thus limiting its biological 
activity. Similar to allogenic materials, its use implies a potential biological risk of 
disease transmission (e.g. prions and retroviruses) and/or immunogenic host tissue 
response, although these risks can be diminished through the manufacturing 
process (de-proteinization). In spite of this inherent risk, however, transmission of 
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bovine spongiform encephalitis (BSE) has not yet been reported associated with the 
implantation of this biomaterial. 
Mechanical properties (brittleness) may vary depending on the source and 
manufacturing process. Since these biomaterials are mainly available for use in 
particulate form, they may have limitations in large defect regeneration interventions. 
Synthetic Bio Ceramics
Calcium sulphate, calcium phosphate (CaP), bioactive glass and combinations are 
the most commonly used bio ceramics available at present.  Their main advantage is 
the controlled manufacturing process which may assure biocompatibility, 
biodegradability and similarity in structure and inorganic composition to natural bone 
minerals. The most investigated CaP bone graft substitutes are hydroxyapatite (HA), 
tricalcium phosphate (-TCP) and their combination, also called biphasic calcium 
phosphate (BCF).  Bio ceramics have shown osteoinductive properties through the 
stimulation of inorganic matrix deposition, osteoblast differentiation, osteoblast 
growth and bone promotion. By modulating their chemical composition and sintering 
temperature their bioactivity and degradation time can be controlled to a certain 
extent.
Their main disadvantage is associated with their limited mechanical properties (load 
bearing resistance) and unpredictable bio-absorption rates. They are mainly 
delivered as particulates, which may limit their use in large bone defects. 
Glass-based ceramics share the same problems of lower mechanical strength 
despite excellent material-bone interactions. Similarly, their degradation times can be 
unpredictable.
To improve their mechanical therapies (brittleness), bio ceramics have been mixed 
with polymers developing composite materials (Laurencin et al.,2014). 
Synthetic Polymers
The most studied synthetic polymers used as biomaterials for bone tissue 
regeneration are aliphatic polyesters like poly (lactic-acid) (PLA), poly (- 
caprolactone) (PCL), and poly (glycolic-acid) (PGA) and their copolymers and 
derivatives. They share the advantage that their manufacture is controllable and 
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tunable in terms of adjusting their physiochemical structure, porosity and hence their 
biodegradability and shape, size and biomechanical properties can be customized. 
Their most important limitation is that they have not demonstrated osteoconductivity 
and hence, their use as bone replacement grafts requires their combination with bio 
ceramics as composite materials or they can be functionalized, for example with 
different coatings. Their process of bio-absorbability usually leads to the release of 
acid compounds that may interfere with wound healing, although this limitation can 
be controlled by the manufacturing process as composite materials can be combined 
with bio ceramics. Furthermore, the bio absorbability of synthetic polymers is highly 
variable, which may impair their mechanical strength in vivo.
Composite bio-materials 
Composite biomaterials are biomaterials generated by combining bio ceramics with 
polymers or xenogeneic biomaterials together with bio ceramics or polymers. Their 
properties will vary depending on their composition and manufacturing processes.
Other synthetic biomaterials
Granules made of titanium particles were marketed for use in bone regeneration, 
although their use is no longer available in the market. 
Recommendations for Future Research
The future of cranio-maxillo-facial bone regeneration will probably entail the 
manufacturing of personalized biomaterials from 3-D digital data obtained from 
patients. Additive manufacturing (e.g. 3-D printing) of different biomaterials (e.g. bio 
ceramics) will allow rapid production of these customized scaffolds that will perfectly 
fit the bone defect anatomy. The addition of synthetic polymers in the design of 
composite biomaterials may mechanically reinforce these 3D constructed 
biomaterials. Similarly, the addition of cells (bio-printing) may add biological activity 
to the 3-D printed constructs
Future biomaterials should have optimized surface characteristics, pore size and 
interconnection. These characteristics will be adjusted to control of their bio-
absorbability, promote osteoinduction and ensure ideal mechanical properties.
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Biomimetic biomaterials should be developed at ambient temperatures by hydrolysis 
and precipitation of calcium deficient apatite, what will result in similar composition 
and crystallinity as natural bone. These biomaterials should be completely replaced 
by new bone through controlled processes of bio-absorbability and osteoinduction.
There is a need of standardized and validated pre-clinical models, with the use of 
small animal models for screening and large-animal models for comparing new 
biomaterials using established standards. In concordance with the ARRIVE 
guidelines to reduce animal research, there is a need for standardized pre-clinical 
models, such as in silico modeling and ex-vivo tissue engineering testing to reduce 
animal research.
.
Membranes for Guided Bone Regeneration used in regenerative 
interventions in the cariomaxillo-facial region
This report addresses the scientific evidence on the effects of membranes used for 
guided bone regeneration (GBR), focusing on their properties and potential biological 
mechanisms, regardless of the clinical applicability.
Ideally, a new developed membrane should pass the cascades of evaluations from 
in vitro to clinical testing until being approved as medical devices according to 
current ISO standards and specifications. In addition, the new European Medical 
Device Regulation (EU-MDR) for implantable medical devices requires confirmation 
of the product claims through prospective clinical studies.
Beside their inherent barrier effect, membranes for guided bone regeneration should 
have certain properties:
- Biocompatibility. The biomaterial shall perform with an appropriate tissue 
response. Hence, the interaction between the material and the tissues should not 
adversely affect the surrounding tissues, the intended healing result or the safety 
of the patient. (Williams, 2017).
- Biological activity. There is increasing evidence that membranes not only function 
due to their occlusive properties, but they actively promote bone regeneration 
within the osseous defect below the membrane. Specifically, this biological activity 
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may include recruitment of cells, angiogenesis, bone formation and bone 
remodeling leading to bone fill of the defect with mature bone. There is 
experimental evidence that collagen membranes allow inward migration of cells 
that express and secrete osteogenic and angiogenic factors. It is not yet 
established whether similar biological processes are shared by membranes of 
different composition.
- Porosity / occlusive properties. A defined porosity or a certain degree of barrier 
effect of the membrane are not prerequisites for their use in guided bone 
regeneration, although these properties may affect the regenerative outcomes. 
There is a wide variability in the pore size and degree of permeability in the 
commercially available membranes for GBR, ranging from: micro-porosity (5 – 20 
um), which may limit the passage of cells, but allows the passage of chemicals, 
biomolecules, viruses; moderate porosity (non-resorbable materials ≤100 µm) that 
also allows the passage of bact ria, cells and tissue integration/migration (tissue 
integration occurs ≥30 – 40 µm); macro-porosity (non-resorbable materials >100 
µm) which allows unrestricted passage of chemicals, biomolecules, viruses, 
bacteria, cells and allows tissue integration and migration. The pore size can 
increase during the process of membrane degradation within the tissue, which 
may in turn influence its bioactivity, passage of nutrient and cells and the ingrowth 
of nutrients and soft and hard tissue cells. The optimal membrane porosity has not 
been defined yet.
- Mechanical properties. The ideal GBR membrane should be sufficiently rigid for an 
adequate space-making capacity and able to withstand the pressure of the 
overlying soft tissues during function in order to prevent its collapse. At the same 
time. It should possess certain degree of plasticity and elasticity to be easily 
contoured and adapted to the anatomy of the defect. In situations where the 
membrane does not possess the required mechanical properties, it should be 
combined with a bone replacement biomaterial/graft that serves as a scaffold, to 
attain the desire volume of regenerated bone.   
- Integration with the tissues. The integration of the membrane with the adjacent 
connective tissues is essential for optimal primary wound closure and healing. In 
fact, lack of integration and membrane exposure is associated with inferior 
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regenerative outcomes. There is evidence that mobility of the membrane and lack 
of hydrophilicity will impair connective tissue integration and bone formation. In 
case of non-resorbable membranes, the degree of tissue integration should be 
coupled with an easy and atraumatic removal. There is lack of information on the 
optimal degree of membrane tissue integration during healing.  
- Exposure tolerance. Membrane exposure and its subsequent bacterial 
contamination may hamper the regenerative outcomes irrespectively whether the 
membrane is biodegradable or non-resorbable. In case of exposure, the exposed 
membrane should be kept in situ and continue to function during the during the 
regenerative process, although in case of overt infections, its removal should be 
considered. When combined with biomaterials, the incidence of infections might 
increase.  
- Biodegradability. Systematic reviews have shown comparable clinical outcomes 
between resorbable and non-resorbable membranes. However, there is clear 
evidence that the membrane must retain its function for a certain amount of time to 
achieve a predictable regenerative outcome. In fact, the longer the membrane 
maintains its function the greater the maturity of the bone is, although in spite of 30 
years of GBR research, the ideal membrane bio absorption time has not yet been 
established. Moreover, the inflammatory response elicited by the degradation of 
the membrane should not adversely affect the regenerative outcome.   
 What are advantages and limitations of currently available membranes used in 
GBR?
PTFE and modifications
Due to its synthetic nature, PTFE membranes have the advantage of not eliciting any 
immunological reaction and being resistant to breakdown by the host tissues. 
Compared with biodegradable membranes, they have superior space making 
capability, mainly when these membranes have titanium reinforcement, which makes 
them the ideal membranes for vertical bone regeneration. Their main limitation is the 
increased frequency of membrane exposure with a subsequent risk for bacterial 
contamination and infection, in fact superior regenerative outcomes with these 
membranes are associated with a closed uneventful healing. Other limitation is the 
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difficulty in their removal due to their soft tissue integration. Moreover, the cost of 
PTFE membranes is higher compared to biodegradable membranes.
Synthetic polymers
The main advantages of polymeric membranes are their manageability, process 
ability, tuned biodegradation, and drug-encapsulating ability. However, their 
degradation might elicit a strong inflammatory response, leading to resorption of the 
regenerated bone. The resorption rate of these types of membranes is largely 
dependent on the type of polymer used. 
Naturally derived membranes: 
Collagen (non-crosslinked)
Collagen-based membranes are the most commonly used naturally derived 
membranes for GBR and their degradation does not exert any potential deleterious 
effect to the tissues.  Their use has not been associated with relevant adverse 
effects since collagen is the principal component of connective tissues, playing 
important role in tissue structural support and in cell matrix communication. Their 
main limitation is their lack of rigidity, which limits their space making capabilities and 
requires their combination with a scaffold, Yet, collagen membranes can be used 
alone for alveolar bone defects which do not require extra fixation and stability such 
as bone dehiscence and fenestration defects. Moreover, as their degradation is fast 
(approximately four weeks) they may not meet the duration of time required for 
optimal tissue regeneration
Chemically modified collagen
In order to slow down the bio-absorption process of collagen membranes, a number 
of different methods of physical/chemical cross-linking have been developed, which 
may also enhance the membrane mechanical properties.  Although chemical cross-
linking has resulted in improvement of collagen stability, release of chemicals 
residues (e.g. amides or aldehydes) has been associated with severe inflammation 
at the implantation site. Generally, the predictability of the collagen membrane not 
only depends on the origin of the collagen material but also its preparation and 
manufacturing process (de-cellularization, sterilization, and method of cross-linking).
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Chitosan, Alginate
Their material properties include biocompatibility, biodegradability, low 
immunogenicity, and a bacteriostatic effect. Experimental results indicate similar 
regenerative outcomes when compared with collagen membranes. Despite the 
experimental studies, their clinical use for GBR has not been documented.
Metals
Titanium is a commonly used material in dentistry. Among its properties are 
biocompatibility, high strength and rigidity for space maintenance, low density and 
weight, the ability to withstand high temperatures, and resistance to corrosion. The 
use of titanium for GBR was inspired from a successful outcome of using a titanium 
mesh for reconstruction of maxillofacial defects. Titanium mesh alone or with bone 
substitutes is a procedure for localized alveolar ridge augmentation prior to, or 
simultaneously with, implant placement.  Occlusive titanium and micro-perforated 
titanium membranes have also been introduced and used for treatment of peri-
implant bone defects and ridge augmentation. Limited experimental data exists on 
CoCr membrane for bone augmentation. Their limitations include difficulties in their 
removal due to connective tissue integration, mainly associated with the titanium 
mesh. Conversely, lack of tissue integration has been reported with the use of solid 
titanium materials.
Which is the role of the exogenous administration of biological cues to the 
membrane?
The use of growth factors and/or cell therapies have provided promising 
experimental results when used in combination with GBR, mainly in combination with 
resorbable membranes. The evidence of efficacy in clinical trials is, however, lacking 
and these strategies may be hampered by financial and regulatory constraints as 
well as for the potential adverse risks associated with these therapies.
Recommendations for Future Research
The bone promoting environments in the membrane and defect compartment during 
GBR can likely be optimized by several strategies targeting both material aspects 
and host-tissue responses. 
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The membrane, the main component of GBR, can be improved depending on the 
functional requirements and the involved biological mechanism. These modifications 
may include: (i) optimizing the physicochemical and mechanical properties, e.g., the 
porosity, structure, thickness, rigidity and plasticity; (ii) incorporating biological 
factors and synthetic bioactive materials (iii) incorporating antibacterial agents and 
antibiotics. 
From scientific, developmental and clinical perspectives, new developments in tissue 
engineering and drug delivery may enhance the barrier concept associated with 
GBR and expand the clinical opportunities for bone regeneration in the future.
Bioactive factors used in regenerative interventions in the 
cariomaxillo-facial region to enhance bone regeneration 
Bioactive agents or factors are defined as natural mediators of tissue repair capable 
of eliciting a response from a living tissue, organism or cell. The majority of pre-
clinical and clinical studies on bone regeneration have focused on Bone 
Morphogenetic Proteins (mainly BMP-2) and Autologous Platelet Concentrates 
(APCs). Less evidence is available for other growth factors (mainly Platelet Derived 
Growth Factor PDGF-BB, Fibroblast Growth Factor FGF-2 and Vascular Endothelial 
Growth Factor VEGF) and amelogenins. The combination of different bioactive 
factors has also been proposed, with the aim to reduce the dosages of each factor 
(and associated side effects) and, at the same time, promote synergistic effects. 
While significant literature has documented the use of bioactive factors (mainly 
amelogenins, FGF-2, PDGF-BB and APCs) for the regeneration of periodontal 
intrabony defects, it is outside the remit of this consensus to comment on periodontal 
regeneration.
What are advantages of the use of bioactive factors in bone regeneration?
The consensus was based on a critical review assessing the outcomes of the use of 
bioactive substances in preclinical models and clinical applications. The preclinical 
bone regeneration models included ridge/socket preservation, alveolar ridge 
augmentation (horizontal and vertical), regeneration of bone defects at the moment 
of implant placement, sinus augmentation and regeneration of critical/sub-critical 
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bone defects. The clinical evidence is based only on RCTs, CCT and Case Series (> 
5 cases) that included histological and/or radiographical assessment of bone 
regeneration for ridge preservation, ridge augmentation, regeneration of bone 
defects at the moment of implant placement and sinus augmentation. 
Bone morphogenetic protein (rh-BMP-2)
Overall, pre-clinical studies suggest that rhBMP-2 (at different dosages) significantly 
promotes, either directly or indirectly, bone regeneration in critical and sub-critical 
size bone defects and de novo bone formation regardless of the carrier adopted. 
rhBMP-2 enhances ridge augmentation in chronic and combined defects and 
promotes ridge preservation. Conflicting results have been reported regarding the 
benefits in peri-implant circumferential defects and sinus augmentation. In 
challenging ridge augmentation or peri-implant defects the combination with a space 
providing material is recommended. 
As a carrier, the Absorbable Collagen Sponge (ACS) can be successfully used, with 
or without space-providing materials. For clinical application, an absorbable collagen 
sponge carrier (ACS) impregnated with rhBMP-2 was approved by the Food and 
Drug Administration for ridge preservation and sinus augmentation. Therefore, most 
of the clinical studies have employed BMP-2/ACS, although a combination of 
rhBMP-2 with different grafts has also been suggested. Clinical studies suggest 1.50 
mg/ml as the optimal dosage for ridge preservation and a range between 1.05 and 
4.2 mg/ml for ridge augmentation purposes, while in some studies on sinus 
augmentation high supra-physiological doses of up to 48mg of BMP-2 per subject 
have been reported.
Based on 3 RCTs, rhBMP-2/ACS combined with osteoconductive grafts and/or a 
titanium mesh for ridge augmentation is comparable to autologous bone and titanium 
mesh or Deproteinized Bovine Bone Mineral based on radiographic/histological 
outcomes. In a recent RCT of 4 months duration, the use of autologous block grafts 
was superior in terms of amounts of mineralized tissue when compared to DBBM 
block grafts loaded with BMP-2. 3 RCTs have used BMP-2 combined with ACS or 
other carriers for ridge preservation. The evidence of using rhBMP-2 in regeneration 
of bone defects following implant placement is scarce. The results of the studies 
using rhBMP-2 as a graft material in sinus floor augmentation are conflicting. 
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Amongst the available bioactive factors BMP-2 is supported with the highest 
evidence, albeit heterogeneous. The existing RCTs suggest that there is a similar 
beneficial effect of rhBMP-2/ACS compared to commercially available bone grafting 
materials for socket preservation and ridge augmentation. Currently, this material 
has not been approved in Europe for clinical use in oro-maxillofacial applications.
Other growth factors (PDGF-BB, FGF-2, VEGF)
Direct administration of PDGF-BB, FGF-2 and VEGF with different carriers and 
indirect administration has been studied in pre-clinical studies with demonstration of 
enhanced bone regeneration when used with GBR. The available evidence for their 
use for ridge preservation is not robust enough to draw conclusions and make 
recommendations 
Studies in chronic alveolar defects have shown that rhPDGF-BB combined with 
block or particulate grafts can significantly promote ridge augmentation. It is unclear 
whether the addition of a barrier membrane has an impact on the final regeneration 
outcome. The pre-clinical evidence that rhFGF-2 associated with different synthetic 
biomaterials can promote ridge augmentation is still not robust. There is limited 
evidence from experimental studies suggesting that rhPDGF-BB alone or combined 
with IGF-1 or bone grafts might enhance the regeneration of peri-implant defects. 
There is insufficient evidence on the use of growth factors other than BMP-2 for 
sinus augmentation.
rhPDGF-BB and rhGDF-5 are the growth factors, apart from rhBMPs, which have 
been evaluated in clinical studies for bone regeneration when combined with 
different bone replacement grafts. The available studies have used 0.5 mL PDGF-BB 
at concentration of 0.3 mg/ml, and between 500 μg to 500 mg rhGDF-5 per gram of 
-TCP. There is limited evidence on the efficacy of rhPDGF-BB for ridge 
preservation and ridge augmentation. RCTs are needed to clarify whether rhPDGF-B 
combined with different grafting materials can promote post-extraction ridge 
preservation and the horizontal and vertical regeneration of alveolar defects. No 
controlled studies have investigated the use of rhPDGF-BB for the treatment of peri-
implant defects and there are only limited studies reporting on the use of rhPDGF-BB 
or rhGDF-5 for sinus augmentation.  Therefore, no robust conclusions could be 
drawn.
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Enamel matrix derivatives (EMD) 
Although various fractions of EMD have shown osteoinductive properties, only few 
pre-clinical studies have investigated the use of amelogenins (EMD) for bone 
regeneration. EMD has limited effect in enhancing bone formation and does not offer 
significant advantages over the use of a membrane or a bone graft or the 
combination of both.
The available clinical evidence does not support the use of EMD in sinus 
augmentation, ridge augmentation, ridge preservation or bone defects following 
implant placement. 
Autologous platelet concentrates (APCs) 
APCs are intended to enhance bone regeneration by triggering the natural healing 
process with a supplement of highly concentrated bioactive factors. One of the main 
challenges in reviewing the scientific evidence is the heterogeneity of the APC 
preparation protocols and accuracy in the use of the terminology.
Some pre-clinical studies have shown that Platelet Rich Plasma (PRP) or Platelet 
Rich Fibrin (PRF) compared to spontaneous healing, fibrin glue derived from Platelet 
Poor Plasma, collagen sponge or hydrogel improve the amount and quality of 
regeneration of experimentally induced bone defects. However, there is no robust 
evidence supporting the addition of these APCs to bone grafts or for de novo bone 
formation.
The evidence on the potential of Plasma Rich in Growth Factors (PRGF) to promote 
bone regeneration in experimentally induced bone defects is limited. Regarding the 
use of all APCs, there is insufficient evidence for ridge/socket preservation, 
regeneration of bone defects after implant placement and sinus augmentation. The 
limited pre-clinical studies on the use of PRP for ridge augmentation suggest that, 
while autologous bone remains the gold standard, the combination of PRP, cells and 
different bone substitutes could be a promising alternative.
Clinical research has shown that the combined therapy of APCs with bone grafts 
and/or cells offer promising results for ridge augmentation procedures. More RCTs 
are needed to clarify which of the APCs is superior. For ridge preservation 
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procedures, APCs may accelerate clinical healing, soft tissue epithelialization and 
reduce postoperative pain, but there is insufficient and contrasting evidence of a 
significant effect on hard tissue regeneration. The clinical effect of APCs on defects 
after implant placement has been studied in a limited number of investigations but 
the available evidence does not allow for robust conclusions. Conflicting outcomes in 
terms of bone formation and implant stability emerged from the available studies on 
the use of APCs for sinus augmentation, with no clear benefits of one APC over the 
other. 
Which are the limitations of the use of growth factors for bone regeneration?
When evaluating the application of growth factors for bone regeneration, there is lack 
of a clear understanding of their mechanism of action, the ideal dosage, frequency 
and mode of administration and the delivery system. Furthermore, there is a clear 
need for developing standardized protocols for controlling their release and 
clearance at the application site. In general, despite some encouraging results, the 
available evidence does not support the use of bioactive factors as a routine 
alternative to the currently used bone regenerative interventions in the caniomaxillo-
facial area.
High dosages of rhBMP-2 have been associated with side effects, including long 
lasting oedema formation, as well as mucosal erythema, osteoclast-mediated bone 
resorption and inappropriate adipogenesis. Combinations of rhBMP-2 with other 
growth factors (preclinical studies) have been suggested to reduce these dosage-
related complications of rhBMP-2. 
Moreover, a concern that could be raised on the use of rhBMP-2 is the development 
of immunological factors, such as anti-rhBMP-2 and anti-bovine collagen type I (6% 
and 20% incidence, respectively, as per FDA report on rhBMP-2/ACS).
Recommendations for Future Research
Well-designed and adequately powered RCTs showing clinical and histological 
outcomes of bioactive agents are required to clarify their potential and actual need in 
regenerative dentistry.
Page 19 of 25
Journal of Clinical Periodontology - PROOF
Journal of Clinical Periodontology - PROOF
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
20
In the future, studies need to be designed to overcome the heterogeneity currently 
present in the literature concerning biological agent’s dosage, formulation, 
concomitant biomaterials used, types of defects, methods of investigation and follow-
up periods.
Research efforts should be also directed towards the development of delivery 
systems enabling controlled spatio-temporal delivery of single or combination of 
bioactive factors. The ultimate aim should be mimicking the synergistic wound 
healing activity of the combinational release profiles of growth factors and 
extracellular matrix components that occurs in physiological wound healing.
Cell therapies used in regenerative interventions in the 
cariomaxillo-facial region to enhance bone regeneration 
This consensus report is based on the review of the evidence from pre-clinical and 
clinical studies on the use of cell therapies for cranio-maxillofacial bone regeneration. 
Three main approaches using cell therapies have been evaluated: a) “minimally 
manipulated” whole tissue fractions; b) ex-vivo expanded “uncommitted” 
stem/progenitor cells, and c) ex-vivo expanded “committed” bone-/periosteum-derived 
cells. Minimally manipulated whole tissue fractions, preserve the physiological 
microenvironment or ‘niche’ of multiple cell types in their natural ratios; these mainly 
include bone marrow aspirates – either whole (BMA) or concentrated (BMAC), adipose 
stromal vascular fractions (A-SVF), and tissue “micrografts”. The major limitation of 
this approach is that mesenchymal stem (and progenitor) cells (MSCs) represent a 
very limited fraction of the implanted cells. 
Ex vivo expansion strategies exponentially increase the number of cells of a specific 
phenotype, i.e., uncommitted or committed, available for transplantation. The most 
commonly used source of uncommitted MSCs is the bone marrow (BMSCs), but more 
recently less invasive sources such as adipose tissue (ASCs) and dental tissues, have 
been tested. Sources of committed cells are the periosteum and cancellous 
bone/marrow of the alveolar bone itself. The major limitation of ex vivo expansion 
strategies is the need for highly sophisticated laboratories according to Good 
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Manufacturing Practices (GMP), thereby significantly increasing the cost of this 
therapy.  
What is the effect of cell therapies (either whole tissues or ex vivo expanded 
cells) added to biomaterials or autologous bone, or combinations thereof, when 
compared with biomaterials or autologous bone alone, or combinations thereof, 
for the different clinical indications in the craniomaxillo-facial area?
Clinical studies have evaluated cell therapies, mainly BMA and BMAC, in combination 
with biomaterials or autologous bone, or combinations thereof vs. relevant controls in 
various indications (e.g. sinus augmentation, horizontal ridge augmentation, alveolar 
cleft defects) and at various observation times. The clinical evidence is mostly based 
on randomized (sinus and ridge augmentation) and non-randomized controlled trials 
(alveolar cleft repair). 
Specifically:
a) in sinus augmentation, significantly more bone regeneration was observed after cell 
therapy in 1 meta-analysis of histomorphometric results (6 studies, vs. scaffolds, 6 
months) and in 1 meta-analysis of micro-computed tomography (µ-CT) results (3 
studies, vs. scaffolds, 4-7 months), while in 1 meta-analysis of histomorphometric 
results no benefit was observed (12 studies, vs. scaffolds, 3-4 months). Based on 
a meta-regression analysis of histomorphometric data from 15 studies, there were 
no differences between the various cell therapy strategies, i.e. whole tissues vs. 
expanded uncommitted cells vs. expanded committed cells, in terms of the amount 
of bone regeneration.
b) in horizontal ridge augmentation, significantly more bone regeneration was 
observed after cell therapy in 1 meta-analysis of histomorphometric results (3 
studies, vs. scaffolds; 1 study, vs. scaffolds + autogenous bone, 4-6 months).
c) in alveolar cleft defects, 1 meta-analysis failed to show a benefit of cell therapy over 
autogenous bone, as evaluated with CT (3 studies, 6 months).
d) limited clinical evidence suggests that the ‘conditioned medium’ or ‘secretome’ from 
MSCs may promote bone regeneration in sinus augmentation [1 study (4 patients), 
vs. scaffold, 6 months].
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The above observations are in general supported by the results of meta-analyses of 
pre-clinical in vivo studies in large animals, which have mainly evaluated ex vivo 
expanded “uncommitted” cells, mainly BMSCs, in combination with biomaterials vs. 
relevant controls in various models (e.g. sinus augmentation, critical size defects, 
alveolar cleft defects) and platforms (e.g. dogs, pigs, sheep/goats) at various 
observation times.
Based on the data from the clinical studies, the following conclusions may be derived:
1. Transplantation of cells, most commonly whole BMA or BMAC, in combination with 
biomaterial scaffolds results in superior bone regeneration compared to 
implantation of scaffolds alone in sinus augmentation and horizontal ridge 
augmentation, and comparable bone regeneration to autogenous bone in alveolar 
cleft repair.
2. Based on studies of sinus augmentation, no superiority of ex vivo expanded cells, 
either uncommitted or committed, over whole tissue fractions (BMA/C or A-SVF) 
was observed. However, the appropriateness of sinus augmentation as a model to 
test cell therapies and detect clinically relevant benefits may be questioned, owing 
to the “self-healing” capacity in this site (Duan, 2017).
3. The analyzed studies, both clinical and pre-clinical, showed a wide range of effect 
sizes and prediction intervals, suggesting a high degree of heterogeneity, and 
emphasizing the need for well-designed future studies to ascertain the true effect 
of cell therapies.
Is osteogenic pre-differentiation in ex vivo expansion strategies beneficial?  
Based on limited evidence from pre-clinical in vivo and uncontrolled clinical studies, 
use of pre-differentiated BMSCs has not demonstrated a significant added effect in 
terms of enhancing bone regeneration compared with using undifferentiated BMSCs, 
while osteogenic pre-differentiation of ASCs or the addition of osteoinductive factors, 
e.g., BMP-2, seemed to enhance bone regeneration. However, no included studies in 
the review (pre-clinical or clinical) directly compared pre-differentiated cells vs. 
undifferentiated cells, either BMSCs or ASCs. 
Based on this limited evidence: 
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 a) In BMSCs, osteogenic pre-differentiation may not show any additional beneficial 
effect.
 b) In ASCs, additional osteogenic stimulation, via pre-differentiation or addition of 
osteoinductive factors, e.g., BMP-2, may be beneficial.  
Recommendations for Future Research
The relatively large effect sizes in favor of cell therapy observed in pre-clinical in vivo 
studies are diminished in clinical trials, suggesting a gap in translation and the need 
for better pre-clinical models.
Vascularization remains a key challenge in cell therapy, especially in large defects, 
since an inadequate vascularization in the internal parts of the cell-scaffold construct 
can impair cell survival and thereby compromise clinical outcomes. Promising pre-
clinical research has been conducted in the area of ‘pre-vascularized’ bone constructs 
but remains to be translated clinically. 
The potential of using allogeneic cells as an “off-the-shelf” therapy has been tested 
with favorable results in a limited number of pre-clinical studies. However, the 
possibilities of immune reactions associated with using allogeneic human cells are still 
unclear and require further investigation (Kiernan, 2018). 
The potential use of ‘cell-free’ strategies, which exploit the paracrine or trophic effects 
of MSC-secretomes to promote regeneration, should be explored. Similarly, 
alternative mechanisms of MSC activity, for example, via “empowerment” of host cells 
and modulation of immune cells in the context of bone regeneration should be 
investigated. 
There is a need to evaluate the cost-effectiveness of cell therapy in comparison to 
current standards of care. Moreover, there is a need of well-designed studies to 
evaluate the efficacy/cost-effectiveness of different cell therapy strategies, i.e., whole 
tissues vs. expanded uncommitted cells vs. expanded committed cells. 
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